Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2017
gptkb:European_Union gptkb:United_States |
| gptkbp:atccode |
L01 BC02
|
| gptkbp:brand |
gptkb:Mavenclad
|
| gptkbp:casnumber |
104202-05-0
|
| gptkbp:chemical_formula |
C10 H12 Cl2 N4 O4
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
long-term efficacy
improvement in disability scores reduction in relapse rates short-term treatment regimen |
| gptkbp:contraindication |
pregnancy
active infections severe renal impairment lactation |
| gptkbp:developed_by |
gptkb:Merck_KGa_A
|
| gptkbp:drug_interactions |
immunosuppressants
live vaccines |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
cladribine
|
| gptkbp:indication |
gptkb:relapsing_forms_of_multiple_sclerosis
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:lifespan |
approximately 7 hours
|
| gptkbp:mechanism_of_action |
purine analog
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:patient_education |
avoid live vaccines during treatment
risk of infections importance of adherence to dosing schedule reporting any signs of infection |
| gptkbp:pharmacokinetics |
bioavailability 100% after oral administration
|
| gptkbp:research_focus |
combination therapies
long-term safety mechanisms of action patient selection criteria optimal dosing strategies |
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
headache nausea increased risk of infections |
| gptkbp:targets |
lymphocytes
|
| gptkbp:used_for |
treatment of multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Mavenclad
|
| gptkbp:bfsLayer |
6
|